Clinical bottom line
GLP-1 receptor agonists (GLP-1 RAs) are emerging as promising agents for cardiovascular and renal protection in patients with chronic kidney disease (CKD), including those with and without diabetes. Recent evidence suggests that beyond their glucose-lowering effects, GLP-1 RAs may reduce albuminuria, slow CKD progression, and decrease cardiovascular events. These benefits appear additive when combined with current standard-of-care therapies such as renin-angiotensin system inhibitors and SGLT2 inhibitors. However, the magnitude of renal benefit and optimal patient selection require further clarification. Clinicians should consider GLP-1 RAs as part of a multifactorial approach to cardio-renal-metabolic risk management in CKD patients, while awaiting more definitive long-term outcomes data.
What the evidence shows
GLP-1 receptor agonists, originally developed for type 2 diabetes mellitus (T2DM), have demonstrated cardiovascular and renal protective effects that extend beyond glycemic control. MacIsaac et al. (2025) highlight semaglutide as a key medication addressing the intertwined cardiovascular-kidney-metabolic syndrome, showing improvements in albuminuria and estimated glomerular filtration rate (eGFR) stabilization in CKD patients with diabetes. Neuen et al. (2025) and Alicic et al. (2025) emphasize the emerging paradigm of combination therapy, where GLP-1 RAs complement SGLT2 inhibitors and mineralocorticoid receptor antagonists to optimize kidney and cardiovascular outcomes in both diabetic and non-diabetic CKD populations.
Mechanistically, GLP-1 RAs exert anti-inflammatory, anti-oxidative, and natriuretic effects that may contribute to renal protection (Dr. Swati Fulmali et al., 2026). Li Mingzhe et al. (2026) further describe cardiovascular benefits including improved endothelial function and reduced atherosclerosis progression, which indirectly support renal health by mitigating systemic vascular injury. These agents also reduce body weight and blood pressure, important modifiable risk factors in CKD progression.
Clinical trials and meta-analyses reviewed by Dr. Swati Fulmali et al. (2026) report consistent reductions in major adverse cardiovascular events (MACE) and progression of albuminuria with GLP-1 RA treatment. While most data derive from diabetic cohorts, emerging evidence suggests potential benefits in non-diabetic CKD, although this remains less well characterized (Neuen et al., 2025). The additive effect of GLP-1 RAs with SGLT2 inhibitors is a promising area, with combination therapy proposed as a new standard of care to address the multifactorial nature of CKD progression (Alicic et al., 2025).
Caveats and uncertainty
Despite encouraging data, several uncertainties remain. Most large trials of GLP-1 RAs have focused on patients with T2DM, limiting generalizability to non-diabetic CKD populations. The renal outcomes reported often use surrogate markers such as albuminuria reduction or eGFR slope rather than hard endpoints like end-stage kidney disease (ESKD) or dialysis initiation. Long-term safety and efficacy data in advanced CKD stages are limited.
The incremental benefit of GLP-1 RAs when added to optimized background therapy including SGLT2 inhibitors and mineralocorticoid receptor antagonists requires further prospective validation. Potential adverse effects such as gastrointestinal intolerance and rare pancreatitis risk may affect tolerability in some patients.
Finally, cost and access considerations may limit widespread adoption, especially in resource-constrained settings. Patient selection criteria, timing of initiation, and optimal dosing strategies in CKD remain areas for future research.
How this may change practice
The accumulating evidence supports considering GLP-1 receptor agonists as part of a comprehensive cardio-renal-metabolic management strategy in CKD patients, particularly those with diabetes and elevated cardiovascular risk. Clinicians should evaluate GLP-1 RAs for patients inadequately controlled on standard therapies or those with progressive albuminuria despite renin-angiotensin system blockade and SGLT2 inhibition.
Incorporating GLP-1 RAs may help reduce cardiovascular events and slow renal decline, potentially delaying the need for renal replacement therapy. Multidisciplinary collaboration involving nephrologists, endocrinologists, and cardiologists will be important to optimize patient outcomes.
Ongoing and future clinical trials will clarify the role of GLP-1 RAs in non-diabetic CKD and define their place in combination regimens. Meanwhile, clinicians should remain vigilant about monitoring for adverse effects and individualizing therapy based on patient comorbidities and preferences.